PVCT earnings analysis
What we found in PVCT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q extract does not contain the income statement, balance sheet, cash-flow statement, MD&A, or segment disclosures, so revenue, margins, EPS, liquidity balances, and free cash flow cannot be assessed. The filing does disclose $1,360,000 of quarterly 2025 Notes proceeds and $1,695,000 for the first six months of 2026, alongside conversions of notes and accrued directors’ fees into Series D-1 preferred stock. Management reported effective disclosure controls, with no material changes in internal control during the quarter, while adding a risk factor covering U.S. trade policy, tariffs, and geopolitical conflicts.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- $1.36M of Quarterly Note Financing
- The company received $1,360,000 of 2025 Notes proceeds during the three months ended June 30, 2026, including $1,245,000 from non-related parties.
- $1.70M of Year-to-Date Financing
- During the six months ended June 30, 2026, the company received $1,695,000 of 2025 Notes proceeds, providing additional liquidity but increasing reliance on financing.
- Convertible Notes Converted
- The company issued 203,859 shares of Series D-1 Convertible Preferred Stock upon conversion of $540,000 of principal and $43,434 of accrued interest on convertible notes.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Trade Policy and Geopolitical Exposure
- The filing adds an updated risk concerning U.S. trade policies, tariffs, international agreements, and geopolitical conflicts. The company received $1,695,000 of 2025 Notes proceeds during the six months ended June 30, 2026, highlighting the potential sensitivity of its financing-dependent operations to capital-market volatility and supply-chain disruptions.
- Concentrated Related-Party Financing
- The company’s financing included $240,000 of 2025 Notes proceeds from an officer and director during the six months ended June 30, 2026, while $100,000 came from a shareholder beneficially owning more than 10% of voting securities. These related-party sources may indicate limited access to diversified external funding.
What they said about what is next.
The supplied filing extract does not include quantitative revenue or EPS guidance. Prior outlook information was reported separately in the June 30, 2026 8-K.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 14, 2026
- Provectus Biopharmaceuticals, Inc. reported a net loss of $1,290,454 for Q1 2026, a 13.2% increase from $1,140,108 in Q1 2025, due to a total absence of grant revenue this quarter and slightly reduced operating…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PVCT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever